Calvin Scott & Company's Phentermine Recall Highlights Critical CGMP Packaging Failures
Calvin Scott & Company, Inc. initiated a Class II recall for Phentermine 15mg capsules due to critical CGMP deviations. Light-sensitive drug products were repackaged into transparent pouches, compromising product integrity. This event, now terminated, underscores the necessity for robust packaging controls in pharmaceutical supply chains, impacting procurement and regulatory compliance for distributors in the United States.
FDA Findings: Critical CGMP Deviations in Phentermine Repackaging
Calvin Scott & Company, Inc., a distributor based in Albuquerque, New Mexico, initiated a Class II recall (D-1525-2020) for its Phentermine 15mg grey/Yellow Capsules. The core issue identified by the FDA was a significant deviation from Current Good Manufacturing Practices (CGMP): the repackaging of light-sensitive drug products into transparent or partially transparent pouches. This practice directly compromises the stability and efficacy of Phentermine, a Schedule IV controlled substance primarily prescribed for weight management. The integrity of light-sensitive active pharmaceutical ingredients (APIs) is paramount, as exposure to light can lead to degradation, reducing potency and potentially forming harmful impurities. The affected product, identified by Lot #:19330 and Exp. Date: 12/20, with NDC 11534-0157-03, was distributed nationwide within the United States. For procurement directors, this incident necessitates a rigorous re-evaluation of all third-party repackaging operations. Ensuring that packaging materials and processes are appropriate for the specific chemical properties of the drug product is a non-negotiable CGMP requirement. Regulatory affairs heads must verify that packaging specifications, particularly for light-sensitive compounds such as Phentermine, are meticulously followed throughout the entire distribution chain, not just at the primary manufacturing site. Business development executives should recognize the potential for brand damage and market disruption when such fundamental quality control failures occur, impacting product availability and consumer trust.
Operational Scope: Calvin Scott & Company's Distribution and Manufacturing Nexus
Calvin Scott & Company, Inc., operating from 209 Eubank Blvd Ne, Albuquerque, NM 87123-2745, functioned as the distributor and repackager responsible for the Phentermine 15mg capsules. While the recall was initiated by Calvin Scott & Company, the original manufacturer of the Phentermine product was Sunrise Pharm., located in Rahway, NJ 07065. This distinction is critical for understanding the locus of the CGMP deviation. The issue did not stem from the primary manufacturing of the drug substance or finished product, but rather from the subsequent handling and packaging processes undertaken by the distributor. The nationwide distribution pattern within the United States for the recalled lot means that the compromised product had broad market exposure. For supply chain VPs, this event underscores that regulatory compliance and quality assurance responsibilities extend beyond the initial API synthesis and drug product manufacturing. Every link in the supply chain, including distributors and repackagers, must adhere to stringent CGMP. Procurement teams must implement robust vendor qualification programs that include comprehensive audits of all partners involved in secondary packaging and distribution, ensuring their quality management systems are adequate to prevent similar incidents. The focus on a US-based distributor for a US-distributed product highlights the consistent and pervasive domestic regulatory scrutiny across the entire pharmaceutical supply chain.
Recall Resolution and the Cost of Non-Compliance
The Class II recall for Phentermine 15mg capsules, initiated by Calvin Scott & Company, Inc. on July 27, 2020, was officially terminated by the FDA on April 11, 2024. The nearly four-year duration from initiation to termination (approximately 3 years and 9 months) highlights the significant operational and financial burden associated with resolving CGMP non-compliance issues. A Class II classification indicates that the product could cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote. For a light-sensitive drug like Phentermine, this classification implies that the degradation due to improper packaging could lead to reduced therapeutic effect, potentially impacting patient outcomes, albeit not immediately life-threatening. Regulatory affairs heads must anticipate that remediation efforts for such deviations are often protracted, requiring substantial resources for investigation, corrective and preventive actions (CAPA), market retrieval, and subsequent FDA verification. The lengthy resolution timeline underscores the importance of proactive compliance management to avoid such costly and time-consuming interventions. Procurement directors should factor in the potential for extended supply disruptions and increased operational costs when evaluating the risk profiles of their suppliers, particularly those with a history of regulatory challenges or those involved in critical secondary processing steps. Business development executives need to understand that prolonged recalls can erode market share and brand reputation, making robust quality systems a competitive differentiator.
Broader Regulatory Landscape: Persistent Focus on Pharmaceutical Quality
While the specific regulatory history of Calvin Scott & Company, Inc. is not detailed, this Phentermine recall aligns with a broader trend of persistent FDA scrutiny on fundamental pharmaceutical quality and Current Good Manufacturing Practices across the industry. Recent parallel events, such as the FDA Class II recall of Essential Wellness Pharma's Progesterone Injection due to sterility assurance failures, and the FDA hearing impacting Amgen's Tavneos market future amid independent data review, underscore the agency's unwavering commitment to patient safety and product integrity. These incidents, though varied in their specific nature—from packaging to sterility and data integrity—collectively signal that no aspect of pharmaceutical manufacturing or distribution is exempt from rigorous oversight. For senior decision-makers, these events serve as a critical reminder that CGMP deficiencies, regardless of their perceived severity or the size of the company involved, will trigger significant enforcement actions. Procurement teams must recognize that a holistic approach to quality assurance, extending beyond API procurement to finished product handling, is essential. Supply chain VPs should prioritize continuous monitoring of regulatory intelligence and invest in robust quality management systems that can proactively identify and mitigate risks across diverse product categories and manufacturing processes. This proactive stance is crucial for maintaining uninterrupted supply, ensuring regulatory compliance, and safeguarding corporate reputation in a highly regulated global market.